-
1
-
-
0036319712
-
Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda
-
DOI 10.1016/S1473-3099(02)00347-X
-
Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD, 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and proposed research and development agenda. Lancet Infect Dis 2: 494-501. (Pubitemid 34826855)
-
(2002)
Lancet Infectious Diseases
, vol.2
, Issue.8
, pp. 494-501
-
-
Guerin, P.J.1
Olliaro, P.2
Sundar, S.3
Boelaert, M.4
Croft, S.L.5
Desjeux, P.6
Wasunna, M.K.7
Bryceson, A.D.M.8
-
2
-
-
0034451615
-
Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic
-
DOI 10.1086/318121
-
Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107. (Pubitemid 32299375)
-
(2000)
Clinical Infectious Diseases
, vol.31
, Issue.4
, pp. 1104-1107
-
-
Sundar, S.1
More, D.K.2
Singh, M.K.3
Singh, V.P.4
Sharma, S.5
Makharia, A.6
Kumar, P.C.K.7
Murray, H.W.8
-
3
-
-
76649099805
-
Single-dose liposomal amphotericin B for visceral leishmaniasis in India
-
Sundar S, Chakravarty P, Agarwal D, Rai M, Murray HM, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504-512.
-
(2010)
N Engl J Med
, vol.362
, pp. 504-512
-
-
Sundar, S.1
Chakravarty, P.2
Agarwal, D.3
Rai, M.4
Murray, H.M.5
-
4
-
-
78149258813
-
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent
-
Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, Boelaert M, 2010. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 4: e818.
-
(2010)
PLoS Negl Trop Dis
, vol.4
-
-
Meheus, F.1
Balasegaram, M.2
Olliaro, P.3
Sundar, S.4
Rijal, S.5
Faiz, M.A.6
Boelaert, M.7
-
5
-
-
0037191710
-
Oral miltefosine for Indian visceral leishmaniasis
-
DOI 10.1056/NEJMoa021556
-
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746. (Pubitemid 35375612)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.22
, pp. 1739-1746
-
-
Sundar, S.1
Jha, T.K.2
Thakur, C.P.3
Engel, J.4
Sindermann, H.5
Fischer, C.6
Junge, K.7
Bryceson, A.8
Berman, J.9
-
6
-
-
34547628081
-
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis
-
DOI 10.1086/519690
-
Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK, 2007. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196: 591-598. (Pubitemid 47206107)
-
(2007)
Journal of Infectious Diseases
, vol.196
, Issue.4
, pp. 591-598
-
-
Bhattacharya, S.K.1
Sinha, P.K.2
Sundar, S.3
Thakur, C.P.4
Jha, T.K.5
Pandey, K.6
Das, V.R.7
Kumar, N.8
Lal, C.9
Verma, N.10
Singh, V.P.11
Ranjan, A.12
Verma, R.B.13
Anders, G.14
Sindermann, H.15
Ganguly, N.K.16
-
7
-
-
36549034731
-
Diagnostic tests for kala-azar: A multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in east Africa and the Indian subcontinent
-
Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling R, 2008. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in east Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 102: 32-40.
-
(2008)
Trans R Soc Trop Med Hyg
, vol.102
, pp. 32-40
-
-
Boelaert, M.1
El-Safi, S.2
Hailu, A.3
Mukhtar, M.4
Rijal, S.5
Sundar, S.6
Wasunna, M.7
Aseffa, A.8
Mbui, J.9
Menten, J.10
Desjeux, P.11
Peeling, R.12
-
8
-
-
0043195461
-
-
Version 2.0, Bethesda, MD: National Cancer Institute
-
Common Toxicity Criteria of the NCI. Version 2.0, 1999. Bethesda, MD: National Cancer Institute.
-
(1999)
Common Toxicity Criteria of the NCI
-
-
-
9
-
-
0033540005
-
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
-
Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J, 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795-1800.
-
(1999)
N Engl J Med
, vol.341
, pp. 1795-1800
-
-
Jha, T.K.1
Sundar, S.2
Thakur, C.P.3
Bachmann, P.4
Karbwang, J.5
Fischer, C.6
Voss, A.7
Berman, J.8
-
10
-
-
34548270384
-
Amphotericin B treatment for Indian visceral leishmaniasis: Response to 15 daily versus alternate-day infusions
-
DOI 10.1086/520665
-
Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW, 2007. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 45: 556-561. (Pubitemid 47328634)
-
(2007)
Clinical Infectious Diseases
, vol.45
, Issue.5
, pp. 556-561
-
-
Sundar, S.1
Chakravarty, J.2
Rai, V.K.3
Agrawal, N.4
Singh, S.P.5
Chauhan, V.6
Murray, H.W.7
|